Ygal Haupt

Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss

Javier Octavio Mejia-Hernandez, Simon P Keam, Reem Saleh, Fenella Muntz, Stephen B Fox, David Byrne, Arielle Kogan, Lokman Pang, Jennifer Huynh, Cassandra Litchfield, Franco Caramia, Guillermina Lozano, Hua He, James M You, Shahneen Sandhu, Scott G Williams, Ygal Haupt, Sue Haupt

Journal article  |  2022  |  CELL DEATH & DISEASE

Understanding prostate cancer onset and progression in order to rationally treat this disease has been critically limited by a dir..

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status

Javier Octavio Mejia-Hernandez, Dinesh Raghu, Franco Caramia, Nicholas Clemons, Kenji Fujihara, Thomas Riseborough, Amina Teunisse, Aart G Jochemsen, Lars Abrahmsen, Giovanni Blandino, Andrea Russo, Cristina Gamell, Stephen B Fox, Catherine Mitchell, Elena A Takano, David Byrne, Panimaya Jeffreena Miranda, Reem Saleh, Heather Thorne, Shahneen Sandhu, et al.

Journal article  |  2022  |  CANCERS

Metastatic prostate cancer is a lethal disease in patients incapable of responding to therapeutic interventions. Invasive prostate..

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

Anna Sofia Trigos, Anupama Pasam, Patricia Banks, Roslyn Wallace, Christina Guo, Simon Keam, Heather Thorne, Catherine Mitchell, Stephen Lade, David Clouston, Alexander Hakansson, Yang Liu, Benjamin Blyth, Declan Murphy, Nathan Lawrentschuk, Damien Bolton, Daniel Moon, Phil Darcy, Ygal Haupt, Scott G Williams, et al.

Journal article  |  2022  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

BACKGROUND: Aberrations in homologous recombination repair (HRR) genes are emerging as important biomarkers for personalized treat..

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status

Kenji M Fujihara, Mariana Corrales Benitez, Carlos S Cabalag, Bonnie Z Zhang, Hyun S Ko, David S Liu, Kaylene J Simpson, Ygal Haupt, Lara Lipton, Sue Haupt, Wayne A Phillips, Nicholas J Clemons

Journal article  |  2021  |  MOLECULAR CANCER THERAPEUTICS

APR-246 (eprenetapopt) is in clinical development with a focus on hematologic malignancies and is promoted as a mutant-p53 reactiv..

Sex disparities matter in cancer development and therapy

Sue Haupt, Franco Caramia, Sabra L Klein, Joshua B Rubin, Ygal Haupt

Journal article  |  2021  |  NATURE REVIEWS CANCER

Curing cancer through precision medicine is the paramount aim of the new wave of molecular and genomic therapies. Currently, wheth..

Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity

Sue Haupt, Ygal Haupt

Journal article  |  2021  |  FRONTIERS IN GENETICS

There are many differences in cancer manifestation between men and women. New understanding of the origin of these point to fundam..

Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer

Neil Portman, Heloisa Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine Fernandez, KeeMing Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne Tilley, Alex Swarbrick, Liz Caldon, Elgene Lim

Conference Proceedings  |  2021  |  CANCER RESEARCH

Abstract Background: Resistance to endocrine therapy is a major clinical challenge in the management of estrogen re..

HIGH DOSE-RATE BRACHYTHERAPY OF LOCALIZED PROSTATE CANCER CONVERTS TUMORS FROM COLD TO HOT

Simon Keam, Heloise Halse, Nguyen ThuNgoc, Minyu Wang, Nicolas Van Kooten Losio, Catherine Mitchell, Franco Caramia, David Byrne, Sue Haupt, Georgina Ryland, Phillip Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott Williams, Paul Neeson

Conference Proceedings  |  2020  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

Background Prostate cancer is frequently cured with high dose-rate brachytherapy (HDRBT) radiation as a front-line treatment. Alt..

Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report

Scott G Williams, Han Xian Aw Yeang, Catherine Mitchell, Franco Caramia, David J Byrne, Stephen B Fox, Sue Haupt, Ralf B Schittenhelm, Paul J Neeson, Ygal Haupt, Simon P Keam

Journal article  |  2020  |  BMC UROLOGY

BACKGROUND: Understanding the drivers of recurrence in aggressive prostate cancer requires detailed molecular and genomic understa..

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

Neil Portman, Heloisa H Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D Tilley, Alex Swarbrick, C Elizabeth Caldon, Elgene Lim

Journal article  |  2020  |  BREAST CANCER RESEARCH

BACKGROUND: Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive br..